Bio-Thera Solutions Reports First Patient Dosing of BAT8007 in P-I Clinical Study for the Treatment of Advanced Solid Tumors
Shots:
- The first patient has been dosed in the P-I clinical study evaluating the safety and tolerability of BAT8007, an antibody-drug conjugate targeting Nectin-4 in patients with advanced solid tumors
- The purpose of the study is to determine the MTD, and RP2D, and to evaluate the PK and preliminary efficacy in patients with advanced solid tumors
- BAT8007 is an ADC targeting Nectin-4 that has been developed using Bio-Thera’s ADC linker-payload incl. a cleavable but systemically stable linker, a small molecule topoisomerase I inhibitor & high DAR. In both in vitro and in vivo pharmacological studies, BAT8007 demonstrated strong anti-tumor activity, good stability, and safety
Ref: Bio-Thera Solutions | Image: Bio-Thera Solutions
Related News:- Bio-Thera Solutions Receives the NMPA’s Approval of BAT1806, a Biosimilar to Actemra
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
